Terms: = Prostate cancer AND FGFR3, CD333, 2261, ENSG00000068078, P22607, JTK4, ACH, HSFGFR3EX, CEK2
58 results:
1. Acetylcholinesterase enzyme among cancer patients a potential diagnostic and prognostic indicator a multicenter case-control study.
Ahmed GY; Osman AA; Mukhtar A
Sci Rep; 2024 Mar; 14(1):5127. PubMed ID: 38429330
[TBL] [Abstract] [Full Text] [Related]
2. Comprehensive multiplexed autoantibody profiling of patients with advanced urothelial cancer.
Ravi P; Freeman D; Thomas J; Ravi A; Mantia C; McGregor BA; Berchuck JE; Epstein I; Budde P; Ahangarian Abhari B; Rupieper E; Gajewski J; Schubert AS; Kilian AL; Bräutigam M; Zucht HD; Sonpavde G
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38309723
[TBL] [Abstract] [Full Text] [Related]
3. FGF2 drives osteosarcoma metastasis through activating FGFR1-4 receptor pathway-mediated ICAM-1 expression.
Huang YC; Chen WC; Yu CL; Chang TK; I-Chin Wei A; Chang TM; Liu JF; Wang SW
Biochem Pharmacol; 2023 Dec; 218():115853. PubMed ID: 37832794
[TBL] [Abstract] [Full Text] [Related]
4. Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials.
Vale CL; Fisher DJ; Godolphin PJ; Rydzewska LH; Boher JM; Burdett S; Chen YH; Clarke NW; Fizazi K; Gravis G; James ND; Liu G; Matheson D; Murphy L; Oldroyd RE; Parmar MKB; Rogozinska E; Sfumato P; Sweeney CJ; Sydes MR; Tombal B; White IR; Tierney JF;
Lancet Oncol; 2023 Jul; 24(7):783-797. PubMed ID: 37414011
[TBL] [Abstract] [Full Text] [Related]
5. Hormone receptor binding, selectivity and cytotoxicity of steroid D-homo lactone loaded chitosan nanoparticles for the treatment of breast and prostate cancer cells.
Kuzminac IZ; Ćelić AS; Bekić SS; Kojić V; Savić MP; Ignjatović NL
Colloids Surf B Biointerfaces; 2022 Aug; 216():112597. PubMed ID: 35636320
[TBL] [Abstract] [Full Text] [Related]
6. Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality.
Keegan NM; Vasselman SE; Barnett ES; Nweji B; Carbone EA; Blum A; Morris MJ; Rathkopf DE; Slovin SF; Danila DC; Autio KA; Scher HI; Kantoff PW; Abida W; Stopsack KH
Prostate; 2022 Aug; 82(11):1107-1116. PubMed ID: 35538298
[TBL] [Abstract] [Full Text] [Related]
7. Somatic Features of Response and Relapse in Non-muscle-invasive Bladder cancer Treated with Bacillus Calmette-Guérin Immunotherapy.
Bacon JVW; Müller DC; Ritch E; Annala M; Dugas SG; Herberts C; Vandekerkhove G; Seifert H; Zellweger T; Black PC; Bubendorf L; Wyatt AW; Rentsch CA
Eur Urol Oncol; 2022 Dec; 5(6):677-686. PubMed ID: 34895867
[TBL] [Abstract] [Full Text] [Related]
8. Erdafitinib as a Novel and Advanced Treatment Strategy of Metastatic Urothelial Carcinoma.
Bansal P; Dwivedi DK; Hatwal D; Sharma P; Gupta V; Goyal S; Maithani M
Anticancer Agents Med Chem; 2021; 21(18):2478-2486. PubMed ID: 33475078
[TBL] [Abstract] [Full Text] [Related]
9. Targetable gene fusions and aberrations in genitourinary oncology.
Pederzoli F; Bandini M; Marandino L; Ali SM; Madison R; Chung J; Ross JS; Necchi A
Nat Rev Urol; 2020 Nov; 17(11):613-625. PubMed ID: 33046892
[TBL] [Abstract] [Full Text] [Related]
10. Differential anti-proliferative and apoptotic effects of lichen species on human prostate carcinoma cells.
Goncu B; Sevgi E; Kizilarslan Hancer C; Gokay G; Ozten N
PLoS One; 2020; 15(9):e0238303. PubMed ID: 32997661
[TBL] [Abstract] [Full Text] [Related]
11. prostate cancer-derived MMP-3 controls intrinsic cell growth and extrinsic angiogenesis.
Frieling JS; Li T; Tauro M; Lynch CC
Neoplasia; 2020 Oct; 22(10):511-521. PubMed ID: 32896761
[TBL] [Abstract] [Full Text] [Related]
12. Antiangiogenic therapy with Nintedanib affects hypoxia, angiogenesis and apoptosis in the ventral prostate of TRAMP animals.
da Silva RF; Banzato TP; Alves LF; Carvalho JE; Agarwal R; Cagnon VHA
Cell Tissue Res; 2020 Feb; 379(2):407-420. PubMed ID: 31473819
[TBL] [Abstract] [Full Text] [Related]
13. A Novel fgfr3 Splice Variant Preferentially Expressed in African American prostate cancer Drives Aggressive Phenotypes and Docetaxel Resistance.
Olender J; Wang BD; Ching T; Garmire LX; Garofano K; Ji Y; Knox T; Latham P; Nguyen K; Rhim J; Lee NH
Mol Cancer Res; 2019 Oct; 17(10):2115-2125. PubMed ID: 31266816
[TBL] [Abstract] [Full Text] [Related]
14. Evolving Role of Genomics in Genitourinary Neoplasms.
Devitt ME; Dreicer R
Acta Med Acad; 2019 Apr; 48(1):68-77. PubMed ID: 31264434
[TBL] [Abstract] [Full Text] [Related]
15. Erdafitinib: First Global Approval.
Markham A
Drugs; 2019 Jun; 79(9):1017-1021. PubMed ID: 31161538
[TBL] [Abstract] [Full Text] [Related]
16.
Kim SH; Park WS; Chung J
Investig Clin Urol; 2019 May; 60(3):148-155. PubMed ID: 31098421
[TBL] [Abstract] [Full Text] [Related]
17. Post-translational modifications in bladder cancer: Expanding the tumor target repertoire.
Oo HZ; Seiler R; Black PC; Daugaard M
Urol Oncol; 2020 Dec; 38(12):858-866. PubMed ID: 30342880
[TBL] [Abstract] [Full Text] [Related]
18. An fgfr3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers.
Mahe M; Dufour F; Neyret-Kahn H; Moreno-Vega A; Beraud C; Shi M; Hamaidi I; Sanchez-Quiles V; Krucker C; Dorland-Galliot M; Chapeaublanc E; Nicolle R; Lang H; Pouponnot C; Massfelder T; Radvanyi F; Bernard-Pierrot I
EMBO Mol Med; 2018 Apr; 10(4):. PubMed ID: 29463565
[TBL] [Abstract] [Full Text] [Related]
19. The antibody-drug conjugate target landscape across a broad range of tumour types.
Moek KL; de Groot DJA; de Vries EGE; Fehrmann RSN
Ann Oncol; 2017 Dec; 28(12):3083-3091. PubMed ID: 29045509
[TBL] [Abstract] [Full Text] [Related]
20. Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder cancer.
Vandekerkhove G; Todenhöfer T; Annala M; Struss WJ; Wong A; Beja K; Ritch E; Brahmbhatt S; Volik SV; Hennenlotter J; Nykter M; Chi KN; North S; Stenzl A; Collins CC; Eigl BJ; Black PC; Wyatt AW
Clin Cancer Res; 2017 Nov; 23(21):6487-6497. PubMed ID: 28760909
[No Abstract] [Full Text] [Related]
[Next]
